Pasar al contenido principal

IDENTIFICACION DE RUTAS INMUNOLOGICAS Y NEUROENDOCRINAS REGULADAS POR BACTERIAS INTESTINALES QUE AYUDEN A COMBATIR LA OBESIDAD

PID2020-119536RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

The Ablation of Sensory Neurons Expressing the Nav1.8 Sodium Channel Improves Glucose Homeostasis and Amplifies the GLP-1 Signaling in Obese Female Mice

  • Romaní-Pérez, Marina
  • Bullich-Vilarrubias, Clara
  • López-Almela, Inmaculada
  • Sanz, Yolanda
[EN] Scope Sensory neurons expressing the sodium channel Nav1.8 contain a repertoire of receptors for nutrient, hormonal, and inflammatory ligands. However, their function in key regulators of energy homeostasis control is not well understood and is completely unexplored in females. Methods and results Mice lacking neurons expressing the sodium channel Nav1.8 were generated using an ablation strategy based on cre recombinase-mediated expression of diphtheria toxin fragment A (DTA) (Nav1.8-cre/DTA mice) to investigate whether these neurons modulate body weight, food intake, gut hormone secretion, gastrointestinal transit, and glucose tolerance in response to nutrient challenges in a sex-dependent manner. Male Nav1.8-cre/DTA mice show resistance to gain weight in response to high-fat high-sugar diet (HFHSD), whereas females lacking Nav1.8+ neurons have improved oral glucose tolerance accompanied by higher insulin levels and attenuated glucagon secretion after an oral glucose load. Female Nav1.8-cre/DTA mice also show higher fasting and postprandial glucagon like peptide-1 (GLP-1) levels with an increased number of GLP-1-positive cells. Finally, ablation of Nav1.8-expressing neurons accelerates the gastrointestinal transit in female mice under HFHSD. Conclusion This data demonstrates sex-dependent differences in the Nav1.8-mediated regulation of energy metabolism, and provides new insights that may help in the design of sex-specific neuromodulation therapies for metabolic disorders induced by diets rich in fats and simple sugars., The authors thank Inmaculada Noguera for excellent technical assistance and the animal technicians for animal care (SCSIE, University of Valencia), and to Dr. Jose Maria Coll Marques (IATA-CSIC) for support in imaging procedures. This study received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 797297 (M.R.P.), the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00), the European Commission - NextGenerationEU, through the "CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+" (PTI-NEURO-AGING+). The grant of the Spanish Ministry of Science and Innovation (MCIN/AEI) to IATA-CSIC as Accredited Center of Excellence (CEX2021-001189-S/ MCIN/AEI/10.13039/501100011033) is acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Intestinal group 1 innate lymphoid cells drive macrophage-induced inflammation and endocrine defects in obesity and promote insulinemia

  • Liébana-García, Rebeca
  • Olivares, Marta
  • Francés-Cuesta, Carlos
  • Rubio, Teresa
  • Rossini, Valerio
  • Quintás, Guillermo
  • Sanz, Yolanda
[EN] Hypercaloric diets overactivate the intestinal immune system and disrupt the microbiome and epithelial cell functions, impairing glucose metabolism. The origins of this inflammatory cascade are poorly characterized. We investigated the involvement of intestinal proinflammatory group 1 innate lymphoid cells (ILC1s) in obesity progression and metabolic disruption. In obese mice, we studied longitudinally the ILC1s response to the diet and ILC1s depletion to address its role in obesity. ILC1s are required for the expansion of pro-inflammatory macrophages and ILC2s. ILC1s depletion induced the ILC3-IL-22 pathway, increasing mucin production, antimicrobial peptides, and neuroendocrine cells. These changes were translated into higher gut hormones and reduced insulinemia and adiposity. ILC1s depletion was also associated with a bloom in Akkermansia muciniphila and decreases in Bilophila spp. Intestinal-ILC1s are upstream activators of inflammatory signals, connecting immunity with the microbiome, the enteroendocrine system, and the intestinal barrier in the control of glucose metabolism and adiposity., This study has been supported by the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00). An PFU contract to RL-G from the Spanish Ministry of Universities (PFU 18/02026) and a Marie Sklodowska Curie Actions (MSCA-IF) "MicroILCs" (GA: 8905454) contract to MO are acknowledged. The grant of Spanish Ministry of Science and Innovation (MCIN/AEI) of Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/ MCIN/AEI / 10.13039/501100011033) is also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Allium Derivate Propyl Propane Thiosulfinate Exerts Anti-Obesogenic Effects in a Murine Model of Diet-Induced Obesity

  • Liébana García, Rebeca
  • Olivares, Marta
  • Rodríguez Ruano, Sonia M.
  • Tolosa Enguís, Verónica
  • Chulia, Isabel
  • Gil Martínez, Lidia
  • Guillamón, Enrique
  • Baños, Alberto
  • Sanz Herranz, Yolanda
Allium species and their organosulfur-derived compounds could prevent obesity and metabolic dysfunction, as they exhibit immunomodulatory and antimicrobial properties. Here, we report the anti-obesogenic potential and dose-dependent effects (0.1 or 1 mg/kg/day) of propyl propane thiosulfinate (PTS) in a murine model of diet-induced obesity. The obesogenic diet increased body weight gain and adipocyte size, and boosted inflammatory marker (Cd11c) expression in the adipose tissue. Conversely, PTS prevented these effects in a dose-dependent manner. Moreover, the higher dose of PTS improved glucose and hepatic homeostasis, modulated lipid metabolism, and raised markers of the thermogenic capacity of brown adipose tissue. In the colon, the obesogenic diet reduced IL-22 levels and increased gut barrier function markers (Cldn3, Muc2, Reg3g, DefaA); however, the highest PTS dose normalized all of these markers to the levels of mice fed a standard diet. Gut microbiota analyses revealed no differences in diversity indexes and only minor taxonomic changes, such as an increase in butyrate producers, Intestimonas and Alistipes, and a decrease in Bifidobacterium in mice receiving the highest PTS dose. In summary, our study provides preclinical evidence for the protective effects of PTS against obesity, which if confirmed in humans, might provide a novel plant-based dietary product to counteract this condition., This study is supported by the Spanish Ministry of Science and Innovation (MICINN) (grants PID2020-119536RB-I00 and CIEN IDI-20170847). The FPU contract to R.L.-G. from Spanish Ministry of Universities (FPU 18/02026) and the contract Juan de la Cierva-Incorporación (IJCI-2017-32485) to MO are fully acknowledge., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tiny contributors to severe obesity inside the gut

  • Sanz Herranz, Yolanda
  • Olivares, Marta
YS is recipient of grants from the Spanish Ministry of Science and Innovation (MICINN) (PID2020-119536RB-I00 and PDC2021-121659-I00), Valencian Agency of Innovation (INNVA1/2021/32) and the European Commission H2020 Programme through the EarlyCause Project (grant agreement: 848158). MO is a beneficiary of a European Marie Skłodowska-Curie Action of H2020 (grant agreement: 890545)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intestinal group 1 innate lymphoid cells drive macrophage-induced inflammation and endocrine defects in obesity and promote insulinemia

  • Liébana García, Rebeca
  • Olivares, Marta
  • Francés Cuesta, Carlos
  • Rubio, Teresa
  • Rossini, Valerio
  • Quintas, Guillermo
  • Sanz Herranz, Yolanda
Hypercaloric diets overactivate the intestinal immune system and disrupt the microbiome and epithelial cell functions, impairing glucose metabolism. The origins of this inflammatory cascade are poorly characterized. We investigated the involvement of intestinal proinflammatory group 1 innate lymphoid cells (ILC1s) in obesity progression and metabolic disruption. In obese mice, we studied longitudinally the ILC1s response to the diet and ILC1s depletion to address its role in obesity. ILC1s are required for the expansion of pro-inflammatory macrophages and ILC2s. ILC1s depletion induced the ILC3-IL-22 pathway, increasing mucin production, antimicrobial peptides, and neuroendocrine cells. These changes were translated into higher gut hormones and reduced insulinemia and adiposity. ILC1s depletion was also associated with a bloom in Akkermansia muciniphila and decreases in Bilophila spp. Intestinal-ILC1s are upstream activators of inflammatory signals, connecting immunity with the microbiome, the enteroendocrine system, and the intestinal barrier in the control of glucose metabolism and adiposity., This study has been supported by the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00). An PFU contract to RL-G from the Spanish Ministry of Universities (PFU 18/02026) and a Marie Sklodowska Curie Actions (MSCA-IF) ”MicroILCs” (GA: 8905454) contract to MO are acknowledged. The grant of Spanish Ministry of Science and Innovation (MCIN/AEI) of Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/MCIN/AEI /10.13039/501100011033) is also acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fast profiling of primary, secondary, conjugated, and sulfated bile acids in human urine and murine feces samples

  • Ramos García, Victoria
  • Ten Doménech, Isabel
  • Vento, Máximo
  • Bullich Vilarrubias, Clara
  • Romaní Pérez, Marina
  • Sanz Herranz, Yolanda
  • Nobili, Angelica
  • Falcone, Marika
  • Di Stefano, Marina
  • Quintás, Guillermo
  • Kuligowski, Julia
Bile acids (BAs) are a complex class of metabolites that have been described as specific biomarkers of gut microbiota activity. The development of analytical methods allowing the quantification of an ample spectrum of BAs in different biological matrices is needed to enable a wider implementation of BAs as complementary measures in studies investigating the functional role of the gut microbiota. This work presents results from the validation of a targeted ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for the determination of 28 BAs and six sulfated BAs, covering primary, secondary, and conjugated BAs. The analysis of 73 urine and 20 feces samples was used to test the applicability of the method. Concentrations of BAs in human urine and murine feces were reported, ranging from 0.5 to 50 nmol/g creatinine and from 0.012 to 332 nmol/g, respectively. Seventy-nine percent of BAs present in human urine samples corresponded to secondary conjugated BAs, while 69% of BAs present in murine feces corresponded to primary conjugated BAs. Glycocholic acid sulfate (GCA-S) was the most abundant BA in human urine samples, while taurolithocholic acid was the lowest concentrated compound detected. In murine feces, the most abundant BAs were α-murocholic, deoxycholic, dehydrocholic, and β-murocholic acids, while GCA-S was the lowest concentrated BA. The presented method is a non-invasive approach for the simultaneous assessment of BAs and sulfated BAs in urine and feces samples, and the results will serve as a knowledge base for future translational studies focusing on the role of the microbiota in health., This work was funded by the European Union’s Horizon 2020 Research and Innovation Programme through the Nutrishield project (https://nutrishield-project.eu/) [Grant Agreement No 818110] and the Carlos III Health Institute (Ministry of Science and Innovation, Spain) and co-funded by the European Union [grant numbers CD19/00176, and CPII21/00003], grant Despega IATA from IATA-CSIC, the Spanish Ministry of Science and Innovation [grant number PID2020-119536RB-I00], and MCIN/AEI/https://doi.org/10.13039/501100011033 and by ERDF A way of making Europe, by the “European Union” [grant number PID2021-125573OB-I00]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tracking microbiota fibre breakdown to treat NASH

  • Flor-Duro, Alejandra
  • Olivares, Marta
  • Sanz Herranz, Yolanda
This study has been supported by the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00). The Miguel Servet contract to M.O. is acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Ablation of Sensory Neurons Expressing the Nav1.8 Sodium Channel Improves Glucose Homeostasis and Amplifies the GLP-1 Signaling in Obese Female Mice

  • Romaní Pérez, Marina
  • Bullich Vilarrubias, Clara
  • López Almela, Inmaculada
  • Sanz Herranz, Yolanda
Sensory neurons expressing the sodium channel Nav1.8 contain a repertoire of receptors for nutrient, hormonal, and inflammatory ligands. However, their function in key regulators of energy homeostasis control is not well understood and is completely unexplored in females., This study received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 797297 (M.R.P.), the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00), the European Commission – NextGenerationEU, through the “CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+” (PTI-NEURO-AGING+). The grant of the Spanish Ministry of Science and Innovation (MCIN/AEI) to IATA-CSIC as Accredited Center of Excellence (CEX2021-001189-S/ MCIN/AEI/10.13039/501100011033) is acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nav1.8-expressing neurons control daily oscillations of food intake, body weight and gut microbiota in mice

  • Bullich Vilarrubias, Clara
  • Romaní Pérez, Marina
  • López Almela, Inmaculada
  • Rubio, Teresa
  • García, Carlos J.
  • Tomás Barberán, Francisco
  • Sanz Herranz, Yolanda
Recent evidence suggests a role of sensory neurons expressing the sodium channel Nav1.8 on the energy homeostasis control. Using a murine diphtheria toxin ablation strategy and ad libitum and time-restricted feeding regimens of control or high-fat high-sugar diets, here we further explore the function of these neurons on food intake and on the regulation of gastrointestinal elements transmitting immune and nutrient sensing.The Nav1.8+ neuron ablation increases food intake in ad libitum and time-restricted feeding, and exacerbates daily body weight variations. Mice lacking Nav1.8+ neurons show impaired prandial regulation of gut hormone secretion and gut microbiota composition, and altered intestinal immunity.Our study demonstrates that Nav1.8+ neurons are required to control food intake and daily body weight changes, as well as to maintain physiological enteroendocrine and immune responses and the rhythmicity of the gut microbiota, which highlights the potential of Nav1.8+ neurons to restore energy balance in metabolic disorders., This study received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 797297 (MRP), the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00) and the European Commission – NextGenerationEU, through the CSIC Interdisciplinary Thematic Platform (PTI + ) NEURO-AGINGl+ (PTI-NEURO-AGING + )”. “Severo Ochoa” grant of National Agency for Research (AEI)- Ministry of Science and Innovation (Ref. CEX2021-001189-S) is also acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comparative Binding Study of Gliptins to Bacterial DPP4-like Enzymes for the Treatment of Type 2 Diabetes Mellitus (T2DM)

  • Carpio, Laureano E.
  • Olivares, Marta
  • Benítez-Páez, Alfonso
  • Serrano-Candelas, Eva
  • Barigye, Stephen J.
  • Sanz Herranz, Yolanda
  • Gozalbes, Rafael
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The role of the gut microbiota and its interplay with host metabolic health, particularly in the context of type 2 diabetes mellitus (T2DM) management, is garnering increasing attention. Dipeptidyl peptidase 4 (DPP4) inhibitors, commonly known as gliptins, constitute a class of drugs extensively used in T2DM treatment. However, their potential interactions with gut microbiota remain poorly understood. In this study, we employed computational methodologies to investigate the binding affinities of various gliptins to DPP4-like homologs produced by intestinal bacteria. The 3D structures of DPP4 homologs from gut microbiota species, including Segatella copri, Phocaeicola vulgatus, Bacteroides uniformis, Parabacteroides merdae, and Alistipes sp., were predicted using computational modeling techniques. Subsequently, molecular dynamics simulations were conducted for 200 ns to ensure the stability of the predicted structures. Stable structures were then utilized to predict the binding interactions with known gliptins through molecular docking algorithms. Our results revealed binding similarities of gliptins toward bacterial DPP4 homologs compared to human DPP4. Specifically, certain gliptins exhibited similar binding scores to bacterial DPP4 homologs as they did with human DPP4, suggesting a potential interaction of these drugs with gut microbiota. These findings could help in understanding the interplay between gliptins and gut microbiota DPP4 homologs, considering the intricate relationship between the host metabolism and microbial communities in the gut., This research was funded through a fellowship for researcher training contracts in companies (INNODOCTO, reference INNTAL32/19/002, INNTA3/2021/16, and INNTA3/2022/20) from the Valencian Agency for Innovation (AVI). This study was also funded by the grant PID2020-119536RB-I00 from the Spanish Ministry of Science, Innovation and Universities (MCIU) and grant APOTIP/2021/035 from Generalitat Valenciana. The authors also acknowledge the award of the Spanish Government MCIU/AEI to the IATA-CSIC as Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/MCIU/AEI/10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bacteroides uniformis CECT 7771 requires adaptive immunity to improve glucose tolerance but not to prevent body weight gain in diet-induced obese mice

  • Romaní Pérez, Marina
  • López Almela, Inmaculada
  • Bullich Vilarrubias, Clara
  • Evtoski, Zoran
  • Benítez-Páez, Alfonso
  • Sanz Herranz, Yolanda
Background: The metabolic disturbances of obesity can be mitigated by strategies modulating the gut microbiota. In this study, we sought to identify whether innate or adaptive immunity mediates the beneficial metabolic effects of the human intestinal bacterium Bacteroides uniformis CECT 7771 in obesity. Methods: We evaluated the effects of orally administered B. uniformis on energy homeostasis, intestinal immunity, hormone levels, and gut microbiota in wild-type and Rag1-deficient mice with diet-induced obesity. We also assessed whether B. uniformis needed to be viable to exert its beneficial effects in obesity and to directly induce immunoregulatory effects. Results: The administration of B. uniformis to obese mice improved glucose tolerance and insulin secretion, restored the caloric intake suppression after an oral glucose challenge, and reduced hyperglycemia. The pre- and post-prandial glucose-related benefits were associated with restoration of the anti-inflammatory tone mediated by type 2 macrophages and regulatory T cells (Tregs) in the lamina propria of the small intestine. Contrastingly, B. uniformis administration failed to improve glucose tolerance in obese Rag1-/- mice, but prevented the increased body weight gain and adiposity. Overall, the beneficial effects seemed to be independent of enteroendocrine effects and of major changes in gut microbiota composition. B. uniformis directly induced Tregs generation from naïve CD4+ T cells in vitro and was not required to be viable to improve glucose homeostasis but its viability was necessary to prevent body weight gain in diet-induced obese wild-type mice. Conclusions: Here we demonstrate that B. uniformis modulates the energy homeostasis in diet-induced obese mice through different mechanisms. The bacterium improves oral glucose tolerance by adaptive immunity-dependent mechanisms that do not require cell viability and prevents body weight gain by adaptive immunity-independent mechanisms which require cell viability., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study received funding from the European Union 7th Framework Program through the MyNewGut project (Grant agreement No. 613979) and from the Spanish Ministry of Science and Innovation (grant PID2020-119536RB-I00). The FPI contract of I.L.-A. from the Ministry of Science and Innovation (Spain) and the contract of C. B-V for promotion of youth employment in R+D+I from Ministry of Science and Innovation (Spain) are fully acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  • Byndloss, Mariana
  • Devkota, Suzanne
  • Duca, Frank
  • Niess, Jan Hendrik
  • Nieuwdorp, Max
  • Orho-Melander, Marju
  • Sanz Herranz, Yolanda
  • Tremaroli, Valentina
  • Zhao, Liping
This article summarises the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organised by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: (1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g. genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomisation in humans; (2) the highly individualised nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; (3) because single time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and (4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal., The 2023 Diabetes, Diabetes Care, and Diabetologia expert forum ‘The microbiome and diabetes: research, translation and clinical applications’, including a subsequent symposium presented on this topic and the preparation of this article, was supported by a grant from the Novo Nordisk Foundation (NNF23SA0085453). MB is a Howard Hughes Medical Institute Freeman Hrabowski Scholar and is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant NIDDK R01DK131104, the Pew Charitable Trusts (2022-A-19568), and the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease (022792). SD is supported by NIDDK grants NIDDK R01DK123446 and 1DP1 DK130687. JHN is supported by the Swiss National Science Foundation (SNSF) grant 310030_219210. MN is supported by a personal ZONMW-VICI grant 2020 (09150182010020) and a DFN-DON grant 2020 (2020.10.002). YS is supported by grants from the Spanish Ministry of Science, Innovation and Universities MICIU/AEI (PID2020-119536RB-I00) and Severo Ochoa Center of Excellence (ref. CEX2021- 001189-S/10.13039/501100011033). VT is a co-principal investigator of a research project funded by the European Union’s Innovative Medicines Initiative (IMI grant 875534)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gut microbiota DPP4-like enzymes are increased in type-2 diabetes and contribute to incretin inactivation

  • Olivares, Marta
  • Hernández Calderón, Paula
  • Cárdenas Brito, Sonia
  • Liébana García, Rebeca
  • Sanz Herranz, Yolanda
  • Benítez-Páez, Alfonso
Background:The gut microbiota controls broad aspects of human metabolism and feeding behavior, but the basis for this control remains largely unclear. Given the key role of human dipeptidyl peptidase 4 (DPP4) in host metabolism, we investigate whether microbiota DPP4-like counterparts perform the same function. Results: We identify novel functional homologs of human DPP4 in several bacterial species inhabiting the human gut, and specific associations between Parabacteroides and Porphyromonas DPP4-like genes and type 2 diabetes (T2D). We also find that the DPP4-like enzyme from the gut symbiont Parabacteroides merdae mimics the proteolytic activity of the human enzyme on peptide YY, neuropeptide Y, gastric inhibitory polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) hormones in vitro. Importantly, administration of E. coli overexpressing the P. merdae DPP4-like enzyme to lipopolysaccharide-treated mice with impaired gut barrier function reduces active GIP and GLP-1 levels, which is attributed to increased DPP4 activity in the portal circulation and the cecal content. Finally, we observe that linagliptin, saxagliptin, sitagliptin, and vildagliptin, antidiabetic drugs with DPP4 inhibitory activity, differentially inhibit the activity of the DPP4-like enzyme from P. merdae. Conclusions: Our findings confirm that proteolytic enzymes produced by the gut microbiota are likely to contribute to the glucose metabolic dysfunction that underlies T2D by inactivating incretins, which might inspire the development of improved antidiabetic therapies., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors acknowledge the following funding bodies that provided support for this study: European Commission 7th Framework Program through the MyNewGut project (Grant agreement No. 613979) and the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00) to YS; Institute of Health Carlos III (ISCIII) via CP19/00132 grant to AB-P with funds from the European Social Fund (ESF/FSE), CIPF Predoctoral Training Fellowships 2022 funded by JANSSEN-CILAG—supporting the contract of PH-C, CIPF core funding for the contract of SC-B; Early Career Grant from the Society for Endocrinology award to MO. Spanish Government MCIN/AEI for the Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/ MCIN/AEI / https://doi.org/10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Obesity and the gut microbiota: implications of neuroendocrine and immune signaling

  • Romaní Pérez, Marina
  • Líebana García, Rebeca
  • Flor Duro, Alejandra
  • Bonillo Jiménez, Daniel
  • Bullich Vilarrubias, Clara
  • Olivares, Marta
  • Sanz Herranz, Yolanda
Obesity is a major health challenge due to its high prevalence and associated comorbidities. The excessive intake of a diet rich in fat and sugars leads to a persistent imbalance between energy intake and energy expenditure, which increases adiposity. Here, we provide an update on relevant diet-microbe-host interactions contributing to or protecting from obesity. In particular, we focus on how unhealthy diets shape the gut microbiota and thus impact crucial intestinal neuroendocrine and immune system functions. We describe how these interactions promote dysfunction in gut-to-brain neuroendocrine pathways involved in food intake control and postprandial metabolism and elevate the intestinal proinflammatory tone, promoting obesity and metabolic complications. In addition, we provide examples of how this knowledge may inspire microbiome-based interventions, such as fecal microbiota transplants, probiotics, and biotherapeutics, to effectively combat obesity-related disorders. We also discuss the current limitations and gaps in knowledge of gut microbiota research in obesity., This study has been funded by the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00), the European Commission – NextGeneration EU, through the CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGINGl+. “(PTI-NEURO-AGING+)” and the “Severo Ochoa” grant of National Agency for Research (AEI)- Spanish Ministry of Science and Innovation (Ref. CEX2021-001189-S). The FPI contract to D. Bonillo from MICIN is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  • Byndloss, Mariana
  • Devkota, Suzanne
  • Duca, Frank
  • Hendrik Niess, Jan
  • Nieuwdorp, Max
  • Orho-Melander, Marju
  • Sanz Herranz, Yolanda
  • Tremaroli, Valentina
  • Zhao, Liping
This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single-time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal., The 2023 Diabetes, Diabetes Care, and Diabetologia expert forum “The Microbiome and Diabetes: Research, Translation and Clinical Applications,” including a subsequent symposium presented on this topic and the preparation of this article, was supported by a grant from the Novo Nordisk Foundation (NNF23SA0085453). M.B. is a Howard Hughes Medical Institute Freeman Hrabowski Scholar and is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant NIDDK R01DK131104, the Pew Charitable Trusts (2022-A-19568), and the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease (022792). S.D. is supported by NIDDK grants NIDDK R01DK123446 and 1DP1 DK130687. J.H.N. is supported by Swiss National Science Foundation (SNSF) grant 310030_219210. M.N. is supported by a personal ZONMW-VICI grant 2020 (09150182010020) and a DFN-DON grant 2020 (2020.10.002). Y.S. is supported by grants from the Spanish Ministry of Science, Innovation and Universities MICIU/AEI (PID2020-119536RB-I00) and Severo Ochoa Center of Excellence (Ref. CEX2021-001189-S/10.13039/501100011033). V.T. is a co-principal investigator of a research project funded by the European Union’s Innovative Medicines Initiative (IMI grant 875534)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  • Byndloss, Mariana
  • Devkota, Suzanne
  • Duca, Frank
  • Niess, Jan Hendrik
  • Nieuwdorp, Max
  • Orho-Melander, Marju
  • Sanz Herranz, Yolanda
  • Tremaroli, Valentina
  • Zhao, Liping
This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single-time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal., The 2023 Diabetes, Diabetes Care, and Diabetologia expert forum “The Microbiome and Diabetes: Research, Translation and Clinical Applications,” including a subsequent symposium presented on this topic and the preparation of this article, was supported by a grant from the Novo Nordisk Foundation (NNF23SA0085453). M.B. is a Howard Hughes Medical Institute Freeman Hrabowski Scholar and is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant NIDDK R01DK131104, the Pew Charitable Trusts (2022-A-19568), and the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease (022792). S.D. is supported by NIDDK grants NIDDK R01DK123446 and 1DP1 DK130687. J.H.N. is supported by Swiss National Science Foundation (SNSF) grant 310030_219210. M.N. is supported by a personal ZONMW-VICI grant 2020 (09150182010020) and a DFN-DON grant 2020 (2020.10.002). Y.S. is supported by grants from the Spanish Ministry of Science, Innovation and Universities MICIU/AEI (PID2020-119536RB-I00) and Severo Ochoa Center of Excellence (Ref. CEX2021-001189-S/10.13039/501100011033). V.T. is a co-principal investigator of a research project funded by the European Union’s Innovative Medicines Initiative (IMI grant 875534)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gut commensal Phascolarctobacterium faecium retunes innate immunity to mitigate obesity and metabolic disease in mice

  • Liébana García, Rebeca
  • López Almela, Inmaculada
  • Olivares, Marta
  • Romaní Pérez, Marina
  • Manghi, Paolo
  • Torres Mayo, Alba
  • Tolosa Enguís, Verónica
  • Flor Duro, Alejandra
  • Bullich Vilarrubias, Clara
  • Rubio, Teresa
  • Rossini, Valerio
  • Segata, Nicola
  • Sanz, Yolanda
The gut microbiota may protect against obesity and chronic metabolic conditions by regulating the immune response to dietary triggers. Yet the specific bacteria that control the overactivation of the immune system in obesity and their mode of action remain largely unknown. Here we surveyed 7,569 human metagenomes and observed an association between the gut symbiont Phascolarctobacterium faecium and non-obese adults regardless of nationality, sex or age. In a mouse model of diet-induced obesity, we confirmed the specificity of P. faecium DSM 32890 anti-obesogenic properties compared with other species of the same genus. P. faecium reversed the inflammatory phenotype associated with obesity. Specifically, P. faecium promoted polarization of alternatively activated macrophages (M2), which reversed the obesity-induced increase in gut-resident type 1 innate lymphoid cells. This resulted in mitigation of glucose intolerance, adiposity and body weight gain irrespective of treatment with live or pasteurized bacteria. The metabolic benefits were independent of the adaptive immune system, but they were abolished by an inhibitor of M2 polarization in mice. P. faecium directly promoted M2-macrophage polarization through TLR2 signalling and these effects seemed to be independent of gut microbiota changes. Overall, we identify a previously undescribed gut commensal bacterium that could help mitigate obesity and metabolic comorbidities by retuning the innate immune response to hypercaloric diets., This study was funded by the European Union 7th Framework Program through the MyNewGut project (Grant Agreement No. 613979) and the Spanish Ministry of Science, Innovation and Universities (MCIU; grant PID2020-119536RB-I00). The FPU and FPI grant contracts from the MCIU to R.L.-G. (FPU18/02026) and I.L.-A. (BES-2015-073930) and a Marie Sklodowska-Curie Actions (MSCA-IF) contract to M.O. (‘MicroILCs’, GA: 8905454) and M.R.-P. (‘miVaO’, GA: 797297) are acknowledged. The grant of accreditation as a Severo Ochoa Center of Excellence from MCIN/AEI (CEX2021- 001189-S/ MCIN/AEI / 10.13039/501100011033) is also acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Safety and Tolerability of the Gut Bacterium Phascolarctobacterium faecium DSM 32890

  • Tamayo, María
  • Tolosa-Enguis, Veronica
  • Alabadi, Blanca
  • Olivares, Marta
  • Romera, Sergio
  • Orti, Leticia
  • Terrado, Elisabet
  • Flor Duro, Alejandra
  • Morillas, Carlos
  • Codoñer, Pilar
  • Real, José T.
  • Sanz Herranz, Yolanda
This article belongs to the Section Prebiotics, Probiotics and Postbiotics, [Background/Objectives] The prevalence of the commensal gut bacterium species, Phascolarctobacterium faecium, has been associated with normal weight in humans. Preclinical evidence suggests that the strain P. faecium DSM 32890 exerts beneficial effects on metabolic and immune function in diet-induced obesity. Herein, we aimed to evaluate the safety and tolerability of this strain in a preclinical study and a pilot interventional trial in humans., [Methods] A repeated-dose oral toxicity study of 28 days was performed in Wistar rats (male and female), during which adverse signs and clinical outcomes were assessed, along with histological, hematologic, biochemical, and immune markers. Subsequently, a pilot human intervention trial was conducted, including 20 participants (11 overweight and 9 normal weight) who received P. faecium DSM 32890 daily for 15 days. Body composition, dietary intake, physical activity, clinical data, perceived health, gastrointestinal symptoms, and blood analyses were assessed to determine tolerability and identify potential adverse effects., [Results] In rats, the administration of the bacterium did not cause behavioral, physiological, histologic, immune, or biochemical alterations. In humans, there was no evidence of adverse effects on general health, hematological and biochemical profiles, bowel habits, or gastrointestinal symptoms. Overweight participants experienced reductions in flatulence and nausea after the intervention., [Conclusions] The consumption of P. faecium DSM 32890 did not raise safety concerns and was well tolerated in rats and humans. The findings represent a step forward in the path toward future, longer-term studies to explore the potential efficacy., This research was funded by Ministry of Science, Innovation and Universities (MCIU, 610 grants: PID2020-119536RB-I00 and PID2023-150693OB-I00.) and by Agencia Valenciana de la Innovación (AVI/IVACE) de la Generalitat Valenciana (Ref INNVA1/2020/25). The accreditation as a Severo Ochoa 611 Center of Excellence to IATA-CSIC from MCIN/AEI (CEX2021-001189-S/MCIN/AEI/612 10.13039/501100011033) is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phascolarctobacterium faecium reduces food intake via PYY signaling, contributing to the mitigation of body weight gain in diet-induced obese mice

  • Bullich Vilarrubias, Clara
  • Romaní Pérez, Marina
  • López-Almela, Inmaculada
  • Pomares Díaz, Carlos
  • Basili Franzin, Silvia
  • Esposito, Giuseppe
  • Benítez-Páez, Alfonso
  • Tolosa Enguís, Verónica
  • Sanz Herranz, Yolanda
Excess energy intake contributes to adiposity in obesity. We investigated whether the human intestinal bacterium Phascolarctobacterium faecium could prevent obesity via enteroendocrine pathways in a mouse model of diet-induced obesity (DIO). Daily administration of P. faecium (2 × 109 cells/mouse) reduced food intake through the early overproduction of the satiety hormone peptide YY (PYY) compared to untreated DIO mice. Moreover, P. faecium increased the intestinal levels of branched-chain amino acids, which, in turn, stimulated PYY secretion in neuroendocrine cell cultures and also modified gut microbiota composition. A pair-feeding study demonstrated that the anorexigenic effect of P. faecium contributes to its effects in attenuating body weight gain in DIO mice, but that other mechanisms are also involved in its metabolic benefits. Specifically, P. faecium accelerated gut transit and serum lipid clearance, thereby limiting adiposity independently of food intake. This study identifies the mode of action of a human intestinal bacterium recently linked to obesity protection, providing valuable insights into host-microbe interactions governing body weight., This study has been funded by the European Union 7th Framework Program through MyNewGut project (Grant agreement No. 613979), the Spanish Ministry of Science, Innovation and Universities (MCIU; grants PID2020-119536RB-I00, PID2023-150693OB-I00) and the European Commission – NextGenerationEU, through CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGINGl+. (PTI-NEURO-AGING+)”. (EU (European Union)), With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relation Between Gut Microbiome and Inflammatory Interleukins in Psoriasis Patients Compared to Healthy Controls: An Observational Study

  • Schneller-Pavelescu, L.
  • Mora Martínez, Carlos
  • Sánchez-Pujol, M.J.
  • Sanz Herranz, Yolanda
  • Caparrós Cayuela, E.
  • Francés Guarinos, R.
  • Ramos Rincón, J.M.
  • Belinchón Romero, I.
The gut microbiota interacts with the immune system and plays an important role in many inflammatory diseases such as psoriasis, although the exact mechanisms in this disease are not yet well understood., This project was funded by a Grant from the 7th Call for Research Support of Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (Alicante Spain) (2020) (projects 2020-0348 and 2020-0289). The study by YS and CM is funded by a project (PID2020-119536RB-100) from the Spanish Ministry of Science, Innovation and Universities (MCIU) and the Spanish Research Agency (AEI)/MCIU to IATA as a Severo Ochoa Center of Excellence (Ref. CEX2021-001189-S)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed